This article is more than 5 years old. Information may no longer be current.
Atezolizumab-chemotherapy combination prolongs PFS in advanced bladder cancer
Click Here to Manage Email Alerts
The addition of atezolizumab to platinum-based chemotherapy extended PFS among patients with previously untreated advanced bladder cancer, according to results released by the agent’s manufacturer.
Atezolizumab (Tecentriq, Genentech) is a monoclonal antibody designed to bind with PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, inhibiting its interactions with both PD-1 and B7.1 receptors.
The randomized phase 3 IMvigor130 study evaluated platinum-based chemotherapy — consisting of gemcitabine with either carboplatin or cisplatin — plus atezolizumab or placebo for 1,213 patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Investigator-assessed PFS and OS served as co-primary endpoints.
The trial met the PFS endpoint. OS data were not yet mature at the time of interim analysis but they appeared encouraging, according to a Genentech-issued press release. Follow-up will continue.
Safety of the atezolizumab-chemotherapy combination appeared consistent with the established safety profiles of each therapy alone. Researchers observed no new safety signals.
Results will be presented at a future medical meeting. Company officials also intend to share the data with the FDA and other health authorities.
Atezolizumab already is approved in the United States for certain patients with urothelial carcinoma, non-small cell lung cancer, small cell lung cancer and triple-negative breast cancer.